Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU

Executive Summary

AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe this week – but AbbVie's drug is the one to watch as analysts have dubbed it a potential blockbuster.

You may also be interested in...



AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.

AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn

With AbbVie's next-generation HCV combo Marivet, newly approved in Europe, the company can look to it and growing sales from Imbruvica to help make up for Humira revenue losses that may start in 2018.

Gilead Completes HCV Clinical Development With Vosevi Approval

Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel